AIDS 2018: early i-Base reports from Amsterdam

20 July 2018. Related: News.

23 – 27 July 2018, Amsterdam

Early reports

i-Base reports, including from the HIV paediatric workshop held before AIDS 2018, will be added to the list of articles below.

• WHO recommends dolutegravir widely but women’s access will depend on contraception provision
• Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study
• No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)
• Using PrEP with feminising hormone therapy support daily PrEP dosing for transwomen
• Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
• DTG/3TC dual therapy non-inferior to triple therapy in GEMINI study
• First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough
• Zero HIV transmissions in PARTNER study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV
• Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians
• Caution on press conference news at AIDS 2018
• i-Base Fit for Purpose report launched at AIDS 2018
• 10th International Workshop on HIV Paediatrics (Pre-conference workshop)
• Preconception safety signal with dolutegravir: data from the Tsepamo study
• 22nd International AIDS Conference (AIDS 2018) – Introduction
• AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference

Introduction

The 22nd International AIDS Conference (AIDS 2018) is being held this year from 23–27 July in Amsterdam.

The programme and abstract listings are already online with open access, though the abstracts themselves are not available and will be embargoed until presented.

• ART – including new drugs and strategies.
• HIV and pregnancy, with first public forum to discuss concerns with dolutegravir.
• Prevention – especially treatment as prevention and PrEP.
• Cure related research – including approaches to overcome the viral reservoir – both in human and animal studies.
• Complications of HIV – including confections, ageing and neurological questions.
• Treatment access – as the international conference with the highest level of community involvement, many sessions focus on expanding access to treatment and prevention at a time when funding is increasingly difficult.

This is going to be an important conference, with UK researchers involved in many of these important studies. These notably include having sites in both the PARTNER and GEMINI studies and for presenting results of the first randomised kick-and-kill cure-related study from the RIVER group – all highlighted as important late-breaker abstracts.

AIDS 2018 programme online:
http://programme.aids2018.org